For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Chronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU appears to be more resistant than chronic spontaneous urticaria (CSU) to standard doses of antihistamines, although claims data analysis reveals positive trends among the more-recent second-generation antihistamines Clarinex and Claritin. Vistaril and montelukast are also key drugs in the CIndU therapy market, and both are often used in combination therapy. Indeed, current treatment guidelines recommend the use of leukotriene antagonists (i.e., montelukast) as add-on treatment. Biologics (e.g., TNF inhibitors) are used mainly as later-line therapy for CIndU, but because no biologics have been approved for the indication, they must be used off-label. Thus, more-effective drugs that are approved for CIndU are needed.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Roche, Novartis, Sanofi, Regeneron, Abbvie, Janssen, Amgen, UCB, Pfizer, Merck, Schering-Plough
Key drugs: Allegra, Zyrtec, Benadryl, montelukast, nifedipine, Silenor, Xolair, Remicade, Enbrel, Cimzia, Simponi, Dupixent